We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $118.30, moving -2.71% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise of 1.23%, and the technology-dominated Nasdaq saw an increase of 0.69%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 0.31% in the past month. In that same time, the Medical sector gained 0.63%, while the S&P 500 gained 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is expected to report EPS of $1.86, down 2.11% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $7.57 billion, reflecting a 0.05% fall from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.17 per share and a revenue of $29.06 billion, signifying shifts of +76.84% and 0%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.13% upward. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 14.3. This signifies a discount in comparison to the average Forward P/E of 18.54 for its industry.
Meanwhile, GILD's PEG ratio is currently 0.65. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.44 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $118.30, moving -2.71% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise of 1.23%, and the technology-dominated Nasdaq saw an increase of 0.69%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 0.31% in the past month. In that same time, the Medical sector gained 0.63%, while the S&P 500 gained 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is expected to report EPS of $1.86, down 2.11% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $7.57 billion, reflecting a 0.05% fall from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.17 per share and a revenue of $29.06 billion, signifying shifts of +76.84% and 0%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.13% upward. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 14.3. This signifies a discount in comparison to the average Forward P/E of 18.54 for its industry.
Meanwhile, GILD's PEG ratio is currently 0.65. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.44 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.